Skip to main content
. 2017 Nov 6;75(1):88–96. doi: 10.1001/jamaneurol.2017.3029

Table 1. Demographics and Neuropsychological Test Scores at the Time of Neuroimaginga .

Characteristic Biomarker Group P Value
/ND
(n = 42)
+/ND
(n = 32)
/ND+
(n = 35)
+/ND+
(n = 66)
Total
(n = 175)
Female sex, No. (%) 15 (35.7) 13 (40.6) 13 (37.1) 30 (45.5) 71 (40.6) .75
Nonwhite race/ethnicity, No. (%) 0 1 (3.1) 2 (5.7) 1 (1.5) 4 (2.3)
Age in 2009, mean (SD), y 85.1 (2.0) 86.8 (3.7) 85.8 (2.8) 86.2 (2.8) 86.0 (2.9) .08
Education, mean (SD), y 14.7 (2.8) 13.9 (2.2) 14.8 (2.8) 15.0 (2.6) 14.7 (2.6) .30
APOE*4 allele carrier, No. (%) 2/40 (5.0) 5/27 (18.5) 2/34 (5.9) 22/62 (35.5) 31/163 (19.0) <.001
MCI in 2009, No. (%) 4 (9.5) 6 (18.8) 7 (20.0) 18 (27.3) 35 (20) .18
Randomized to receive Ginkgo biloba, 2000-2008, No. (%) 24 (57.1) 18 (56.3) 35 (53.0) 11 (31.4) 88 (50.3) .09
Memory, mean (SD), score
CVLT immediate recall (No. of words) 46.71 (10.58) 42.06 (11.90) 42.14 (11.41) 40.50 (12.55) 42.60 (15) .07
CVLT delayed recall (No. of words) 9.38 (3.19) 8.38 (3.32) 7.40 (3.87) 7.57 (4.03) 8.12 (3.74) .05
R-O figure immediate recall 17.50 (3.41) 16.84 (3.62) 16.30 (3.82) 14.83 (4.21) 16.13 (3.97) .004
R-O figure delayed recall (maximum 24 points) 16.85 (3.70) 17.16 (4.17) 15.64 (4.28) 14.92 (4.42) 15.93 (4.17) .03
Executive function, mean (SD), score
Trails B (s) 100.86 (44.66) 127.38 (52.33) 105.94 (43.29) 122.68 (53.60) 114 (50.08) .05
Visual-spatial reasoning, mean (SD), score
R-O figure copy (maximum 24 points) 21.00 (2.37) 20.30 (2.17) 20.53 (2.46) 19.95 (2.56) 20.38 (2.44) .18
Language, mean (SD), score
Semantic fluency (No. of words) 27.38 (9.03) 28.13 (7.15) 26.85 (8.42) 28.07 (7.90) 27.67 (8.15) .88
Phonemic fluency (No. of words) 16.50 (3.68) 15.00 (3.62) 15.11 (3.86) 14.10 (4.07) 15.05 (3.93) .02
Attention and psychomotor speed, mean (SD), score
Trails A (s) 42.19 (13.21) 47.06 (15.40) 39.91 (12.74) 50.60 (19.84) 45.77 (16.75) .007

Abbreviations: Aβ, amyloid β; CVLT, California Verbal Learning Test; MCI, mild cognitive impairment; ND, neurodegeneration; R-O, Rey-Osterrieth.

a

Neuroimaging was performed in 2009. A reduced battery was administered in 2009, omitting Block Design, Stroop Test, and Boston Naming Test.